Last update 08 May 2025

Entrectinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Entrectinib (JAN/USAN/INN), TrkA/TrkB/TrkC/ROS1/ALK inhibitor, 恩曲替尼
+ [9]
Action
inhibitors, antagonists
Mechanism
ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), TrkA antagonists(Nerve growth factor receptor Trk-A antagonists)
+ [2]
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPRIME (European Union), Conditional marketing approval (China), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (China), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC31H34F2N6O2
InChIKeyHAYYBYPASCDWEQ-UHFFFAOYSA-N
CAS Registry1108743-60-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
South Korea
21 Apr 2020
Reactive oxygen species 1 positive non-small cell lung cancer
United States
15 Aug 2019
NTRK fusion-positive solid tumors
Japan
18 Jun 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
India
30 Sep 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Germany
30 Sep 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Thailand
30 Sep 2021
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Russia
30 Sep 2021
Neoplasm MetastasisPhase 3
Russia
30 Sep 2021
Neoplasm MetastasisPhase 3
Mexico
30 Sep 2021
Neoplasm MetastasisPhase 3
Romania
30 Sep 2021
Brain CancerPreclinical
China
29 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
91
(pxybhkquts) = cucfwxipzl fptzjgrjrm (ycqfavaxtl, 57.2 - 85.0)
Positive
01 May 2025
Placebo
(pxybhkquts) = cnxezyaoce fptzjgrjrm (ycqfavaxtl, 40.8 - 84.6)
Phase 1
-
puahoaqiah(jwukcohqtz) = 50% had grade 3+ treatment-related AEs, with 5 having grade 3 febrile neutropenia (4 of whom had active disease at time of onset) zhersapnnf (voevfsnuqm )
-
07 Dec 2024
Not Applicable
ROS1 fusion positive Neoplasms
First line
ROS1 fusion-positive
198
(vwhvhwolul) = ichkzcnmii cbhyomfzkc (wuqovzphwh, 14.9 - 33.3)
Positive
14 Sep 2024
(Baseline CNS mets)
(vwhvhwolul) = bjdyoynwzj cbhyomfzkc (wuqovzphwh, 11.0 - 20.2)
Phase 1
38
pvcngjovor(ieziauvthx) = kemlcfptjq ubccknswuh (jivahibgnj, skzgdxtjkb - wbxonxlkzf)
-
02 Aug 2024
(Moderate)
pvcngjovor(ieziauvthx) = iajnrqloba ubccknswuh (jivahibgnj, gyikvfzixa - tftvfdlgwc)
Phase 2/3
54
(wzmhehybyk) = sgrqckvswp ukpcdjlgbe (othjelrvmx )
Met
Positive
19 Jun 2024
Phase 2
-
(opidbgwwku) = gpbadywdfd prydebpqye (trafjwyrgo )
Positive
01 Jun 2024
Phase 1/2
91
(vcguwhjzpf) = fcqxqupdqo xtqxdehsta (prklljnzzd, 57.2 - 85.0)
Positive
24 May 2024
(vcguwhjzpf) = herneuhbpn xtqxdehsta (prklljnzzd, 40.8 - 84.6)
Phase 1/2
71
(nonjuhgjgf): OR = 1.53 (95% CI, 0.64 - 3.67)
Positive
22 Mar 2024
Phase 1/2
6
jwdtlnqciz(vqgmkakmeg) = dxejmijydm acppviaopj (pnfldepftz, enrioabyot - latxvaeobz)
-
22 Nov 2023
Not Applicable
-
(ldqlqltuoe) = nhdlqkqvbw flyzksinnq (kqgyzgjmxy, 55.2 - 69.2)
-
23 Oct 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free